课题基金 / 基金详情

桂楼组分通过RHO GTPases抑制子宫腺肌病内膜细胞EMT的机制研究

批准号:
82104916
项目类别:
青年科学基金项目(C类)
资助金额:
30.0 万元
负责人:
刘志勇
依托单位:
学科分类:
中医妇科学
结题年份:
2024
批准年份:
2021
项目状态:
已结题
项目参与者:
刘志勇

项目摘要

结项摘要

相似基金

相关文献

中文摘要
子宫腺肌病(AM)为妇科常见疑难病,严重危害健康,疾病进程与子宫内膜上皮-间充质转化(EMT)密切相关,具体机制尚待阐明。RHO GTPases通路在调控EMT发生和细胞侵袭表型获得中起重要作用,“胞宫久瘀至癥”是AM核心病机,课题组创制“通脉化癥汤”临床证实有显效,前期研究发现其核心药对桂枝和重楼各自提取物均能有效抑制AM异位内膜细胞(AMDC)的p-CFL水平、EMT指标和侵袭力,提出假说“桂楼组分可能经RHO GTPases介导CFL磷酸化,调控细胞骨架重排而降低细胞侵袭能力,抑制EMT过程和阻断AM病灶进展”。本研究将筛选桂楼有效组分联用(TCPP)处理AMDC,检测RHO GTPases经CFL介导细胞骨架重排及对EMT、侵袭和迁移的影响,并制备含TCPP中药宫内缓释系统,以宫腔局部给药大鼠AM模型进行验证,明确桂楼组分抑制AM进程的关键靶点,为含中药宫内缓释系统研发奠定基础。
英文摘要
Adenomyosis (AM) is a commonly diagnosed gynecological disease, which threatens women's health. The progression of AM is related to epithelial-mesenchymal transition (EMT) of endometrial cells, but the specific mechanism remains to be clarified. RHO GTPase signaling pathways are important regulators of EMT and cell invasion. The key pathogenesis of AM in traditional Chinese medicine is "Baogong Jiuyu Zhizheng". The "Tongmai Huazheng Decoction" created by our group has been proved to be effective in the treatment of AM. Cinnamomi Ramulus and Paris polyphylla are critical drug pair of the decoction. Our data have showed that both of the extracts of Cinnamomi Ramulus and Paris polyphylla can effectively inhibit the p-CFL level, EMT process and the the invasion of adenomyosis derived cells (AMDC) from ectopic endometrium. Thus, we speculated that active ingredients of Cinnamomi Ramulus and Paris polyphylla may regulate phosphorylation of CFL through RHO GTPases, suppress invasion ability of AMDC by regulating cytoskeleton rearrangement, and block the progression of EMT in AM. In this study, the critical components in Cinnamomi Ramulus and Paris Polyphylla that inhibit invasion and migration ability of AMDC will be identified. The influences of effective ingredients used in combination (TCPP) on cytoskeleton related RHO GTPase pathways, EMT, cell invasion and migration will be elucidated. For the development of sustained release system, we will verify the effects of TCPP containing intrauterine sustained-release system on AM in rats and expound the essential targets of intrauterine administration.
子宫腺肌病(AM)是妇科常见疑难病,主要特征为子宫内膜腺体或间质侵入肌层生长,所导致的痛经、月经量多、不孕等临床症状严重危害女性身心健康,已报道AM呈现发病率逐年升高和患者年轻化趋势,是阻碍国家优化生育政策的重要因素,其发病机理研究和治疗方案优化受到广泛关注。.AM发病与上皮-间充质转化(EMT)密切相关,RHO GTPases通路在调控EMT中发挥关键作用,课题组针对AM“胞宫久瘀至癥”病机创制的“通脉化癥汤”临床效果明显,本项目筛选组方中核心桂枝-重楼药对活性成分联用(PT),体外检测了其对异位病灶衍生细胞(AMDC)骨架调控和EMT进程的影响,明确RHOA的关键功能,进一步构建含PT成分的宫内缓释药棒植入AM体内模型,检测PT药物腹腔注射和局部给药对AM的治疗效果,揭示体内作用机理。.通过本研究,我们筛选得到抑制AMDC细胞运动能力明显的重楼皂苷II(PPII)和反式桂皮醛(TCA),正交实验确定了PT联用的最佳药物浓度,同时发现PT能够有效抑制正常以及RHOA激活条件下AMDC细胞的迁移、侵袭能力和细胞骨架形成,机制研究揭示PT抑制ROCK1-LIMK-CFL1通路活性及EMT进程。亚慢性毒性评估提示PT使用未影响小鼠肝、脾、肾和子宫组织形态,以及肝、肾功能血清学指标,同时PT和含桂楼组分缓释药棒可以抑制AM模型小鼠中腺体向肌层侵袭,抑制细胞骨架调控ROCK1、p-LIMK和p-CFL1表达,下调EMT调控CDH2、SNAI1、SNAI2、TWIST1和MMPs水平,上调CDH1表达。.我们的结果充分证实PT联用通过RHOA-ROCK1-LIMK-CFL1通路调控细胞骨架重排,抑制AMDC细胞的EMT进程及迁移和侵袭能力,阻断AM病灶进展。目前通脉化癥汤已转化为医疗机构中药制剂,并应用于临床,患者反馈良好,本项目对其关键药对药效物质基础的研究为临床转化提供了坚实基础。
国内基金
海外基金